Abstract
Introduction
The fourth quarter of 2007 was fairly quiet in the pricing and reimbursement
arena. In the United States, the presidential election, legislation in
California, and a new initiative from health plans focused attention on the
uninsured and universal coverage. A public consultation on the future of
pharmaceuticals highlighted the challenges confronting drug manufacturers in
Europe, while the Japanese government seemingly changed course on overhauling
its pharmaceutical pricing and reimbursement system.
Get the Answers You Need to Shape Your Strategy
- Pending U.S. legislation would allow the Department of Health and Human
Services to create a national Medicare formulary. How would HHS use this
formulary in its price negotiations with pharmaceutical manufacturers?
- U.S. employers and health plans are recognizing the fi nancial and health
benefi ts of promoting greater use of generic drugs and improved adherence to
chronic disease therapy. What strategies are they pursuing in their efforts
to improve patient adherence with chronic disease therapy and encourage the
use of generics?
- Pressure to tackle the growth in the ranks of uninsured U.S. residents is
mounting. Which states have enacted their own universal coverage
legislation? How will the presidential election affect this issue at the
national level?
Scope
- Overview: major events in the fourth quarter of 2007 in the pricing,
reimbursement, and prescribing environment in the major pharmaceutical markets
under study.
- United States: leading stories in 2007, including SCHIP, decline in drug
imports, copayment reductions and waivers for generics and chronic disease
therapies, and many others.
- European Union: responses to public consultation on the future of
pharmaceuticals in Europe.
- France: pressures on pharmaceutical industry, potential reforms for
chronic disease treatments.
- Germany: new reference pricing groups, health economic evaluation, growth
in rebate contracts.
- Italy: market trends in 2007.
- Spain: amendments to the reference pricing system.
- United Kingdom: proposed amendments to NICE' s methods for technology
appraisals, OFT report on direct-to-pharmacy distribution, abolition of
prescription charges in Scotland.
- Japan: delay in overhaul of pricing and reimbursement system, efforts to
increase use of generics.
- Outlook and implications for the pharmaceutical industry: the outlook for
pharma in the United States, Europe, and Japan.
View Cart
